Are GMP Violations The “Next Hot Thing” In False Claims Act Litigation?
This article was originally published in The Gold Sheet
Executive Summary
Former prosecutors say there are cases pending under seal, but it is uncertain whether the government will intervene. They note the difficulty in proving the allegations and say FDA’s regulatory regime may be a better route for handling GMP issues.
You may also be interested in...
Justice Targets ‘Serious’ GMP Issues, Hears More from Whistleblowers
The Justice Department is imposing harsh penalties on manufacturers that commit serious GMP violations and this trend will continue in the foreseeable future. DOJ is also getting more calls from FDA and whistleblowers alleging GMP violations under the False Claims Act.
GSK’s $750 Mil. DoJ Settlement: When GMP Violations Equal Healthcare Fraud
GlaxoSmithKline’s $750 million settlement with the Department of Justice raises a worrisome question for industry: will violations of current good manufacturing practices become a target for whistleblower suits?
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.